EUVIMEDEUVIMED entdecken
Klinische Studie (Phase III)Randomisierte kontrollierte StudieMultizentrische StudieOpen Access · CC BY-NC-ND 4.0

Long-term efficacy and safety of dupilumab with concomitant topical corticosteroids in Japanese pediatric patients with moderate-to-severe atopic dermatitis: Results from a phase 3 open-label extension study

Yoko Kataoka, Motohiro Ebisawa, Akio Tanaka, Mizuho Nagao, Elizabeth Laws, Hisakatsu Nawata, Kazuhiko Arima, Daisuke Watanabe, Xin Lu, Jennifer Maloney, Ariane Dubost-Brama, Ashish Bansal und 1 weitere

Allergology International · 2026

DOI: 10.1016/j.alit.2025.09.002 ↗

Kurz gefasst

Klinische Studie (Phase III) in der Zeitschrift Allergology International, 2026. Verfasst von Yoko Kataoka und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology, Osaka Habikino Medical Center, Habikino, Japan. Electronic address: kataokay@ra.opho.jp. Hauptthemen laut MEDLINE: Dermatitis, Atopic, Antibodies, Monoclonal, Humanized, Adrenal Cortex Hormones. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 24 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Sanofi KK.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Dupilumab is approved in Japan for the treatment of atopic dermatitis in patients aged 6 months to 18 years. However, long-term data are lacking in this patient population. Here we report the final analysis of a long-term open-label extension (OLE) of a phase 3 study that assessed dupilumab in Japanese patients aged ≥6 months to

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Dermatitis, AtopicAntibodies, Monoclonal, HumanizedAdrenal Cortex HormonesHumansChildMaleFemaleAdolescentChild, PreschoolTreatment OutcomeSeverity of Illness IndexInfantJapanAdministration, TopicalEast Asian People

Stichwörter der Autor:innen

AtopicDermatitisDupilumabJapanesePediatricsTopical corticosteroids

Substanzen

dupilumabAntibodies, Monoclonal, HumanizedAdrenal Cortex Hormones

Autor:innen und Institutionen

  • Department of Dermatology, Osaka Habikino Medical Center, Habikino, Japan. Electronic address: kataokay@ra.opho.jp.
  • Clinical Research Center for Allergy and Rheumatology, NHO Sagamihara National Hospital, Sagamihara, Japan.
  • Department of Dermatology, Graduate School of Biomedical Sciences, Hiroshima University, Hiroshima, Japan.
  • Department of Clinical Research, NHO Mie National Hospital, Tsu, Japan.
  • Sanofi, Bridgewater, NJ, USA.
  • Immunology Medical, Sanofi K.K., Tokyo, Japan.

Förderung

  • Sanofi KK

Zitieren

APA

Kataoka, Y., Ebisawa, M., Tanaka, A., Nagao, M., Laws, E., Nawata, H., Arima, K., Watanabe, D., Lu, X., Maloney, J., Dubost-Brama, A., Bansal, A., & Yahata, K. (2026). Long-term efficacy and safety of dupilumab with concomitant topical corticosteroids in Japanese pediatric patients with moderate-to-severe atopic dermatitis: Results from a phase 3 open-label extension study. Allergology International. https://doi.org/10.1016/j.alit.2025.09.002

Vancouver

Kataoka Y, Ebisawa M, Tanaka A, Nagao M, Laws E, Nawata H, et al. Long-term efficacy and safety of dupilumab with concomitant topical corticosteroids in Japanese pediatric patients with moderate-to-severe atopic dermatitis: Results from a phase 3 open-label extension study. Allergology International. 2026. doi:10.1016/j.alit.2025.09.002

BibTeX
@article{Kataoka2026,
  author = {Kataoka, Yoko and Ebisawa, Motohiro and Tanaka, Akio and Nagao, Mizuho and Laws, Elizabeth and Nawata, Hisakatsu and Arima, Kazuhiko and Watanabe, Daisuke and Lu, Xin and Maloney, Jennifer and Dubost-Brama, Ariane and Bansal, Ashish and Yahata, Kenji},
  title = {Long-term efficacy and safety of dupilumab with concomitant topical corticosteroids in Japanese pediatric patients with moderate-to-severe atopic dermatitis: Results from a phase 3 open-label extension study},
  journal = {Allergology International},
  year = {2026},
  doi = {10.1016/j.alit.2025.09.002}
}
Kostenlos starten →